BioMaxima SA
WSE:BMX
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| PL |
B
|
BioMaxima SA
WSE:BMX
|
53m PLN |
Loading...
|
|
| JP |
|
Hoya Corp
TSE:7741
|
8.8T JPY |
Loading...
|
|
| CH |
|
Alcon AG
SIX:ALC
|
30.8B CHF |
Loading...
|
|
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
57.5B USD |
Loading...
|
|
| DK |
|
Coloplast A/S
CSE:COLO B
|
120.8B DKK |
Loading...
|
|
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
11.7B USD |
Loading...
|
|
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.7B GBP |
Loading...
|
|
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
42.2B CNY |
Loading...
|
|
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.9B USD |
Loading...
|
|
| CH |
|
Ypsomed Holding AG
SIX:YPSN
|
4.2B CHF |
Loading...
|
|
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
7.3T KRW |
Loading...
|
Market Distribution
| Min | -9 940 700% |
| 30th Percentile | -3.7% |
| Median | 2.9% |
| 70th Percentile | 9.1% |
| Max | 196 605.3% |
Other Profitability Ratios
BioMaxima SA
Glance View
Biomaxima SA operates in the field of biotechnology and laboratory diagnostics. The company is headquartered in Lublin, Woj. Lubelskie. The company went IPO on 2010-06-08. The company manufactures and distributes reagents and equipment for the laboratory diagnosis. The company produces reagents for the in vitro diagnosis. The main product groups offered by BioMaxima include: diagnostic reagents and analyzers for clinical biochemistry; rapid tests and readers for detecting infectious diseases, cancer markers, cardiac markers and drugs of abuse; urine analysis systems; hematology analyzers and reagents; ion-selective analyzers and reagents; reagents and immunological analyzers of cardiac markers; glucometers; analyzers for gasometric tests and critical blood parameters tests. The firm supplies hospitals and laboratories in Poland, as well as in Lithuania, Latvia, Romania and France. On March 20, 2014, the Company merged with its wholly owned subsidiary Cebo Sp z o o.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for BioMaxima SA is 1.1%, which is below its 3-year median of 3.3%.
Over the last 3 years, BioMaxima SA’s Net Margin has decreased from 19.8% to 1.1%. During this period, it reached a low of -0.9% on Jun 30, 2024 and a high of 19.9% on Dec 31, 2022.
